Dupilumab (Dupixent) for the treatment of eczema in teenagers

In 2019, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether dupilumab has any advantages or disadvantages compared to optimized individual treatment for moderate to severe in young patients aged 12 years and over who are able to have systemic treatment.

The manufacturer didn't provide any suitable studies involving teenagers. So IQWiG used a study involving adults instead, specifically looking at the results related to people between the ages of 18 and 39. In this age group, 52 people were given dupilumab for about half a year (300 mg of dupilumab every 2 weeks) and 189 were given a placebo (fake medication). In addition, both groups had treatment with glucocorticoid (steroid) creams. If their symptoms got worse, the treatment was individually adjusted further. The study included only people who had had moderate to severe for at least three years.

What are the advantages of dupilumab?

Symptoms of the disease: Overall, the study suggests that dupilumab has an advantage in terms of symptoms: People who used dupilumab experienced fewer symptoms such as dry or scaly skin.

Itching: Early results suggest that dupilumab has an advantage here: Itching improved in about 62 out of 100 people within one year. In the group that had optimized individual treatment, this only happened in about 31 out of 100 people.

Health-related quality of life: The study suggests that dupilumab is better here, too: About 33 out of 100 people who used dupilumab reported that their quality of life improved, compared to about 15 out of 100 people who had individually optimized treatment.

What are the disadvantages of dupilumab?

Eye problems: The study suggests that dupilumab has a disadvantage here.

No difference

There was no real difference between the two groups regarding sleep problems.

What remains unanswered?

The manufacturer didn't provide any usable data about overall health.

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Dupilumab (Atopic dermatitis) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A17-63. February 27, 2018. (IQWiG reports; Volume 601).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Dupilumab (Atopic dermatitis in adolescents)  – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A19-75. November 28, 2019. (IQWiG reports; Volume 847).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on December 19, 2019
Next planned update: 2022

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.